Paul A Gurbel MDDirector, Inova Center for Thrombosis Research and Drug Development, Director, Interventional Cardiology and Cardiovascular Medicine Research, Inova Heart and Vascular Institute, Falls Church, VA
Dr. Paul A. Gurbel is an interventional cardiologist. He founded the Sinai Center for Thrombosis Research in 1997. His research focuses on defining the effects antiplatelet agents, antiplatelet agent development, and understanding the relation of platelet reactivity to ischemic event occurrence in patients with cardiovascular disease. His laboratory pioneered the concept of antiplatelet response variability and was the first to demonstrate the relation between high platelet reactivity to adenosine diphosphate and ischemic event occurrence in the PCI population. These observations served as the rationale for the development of new P2Y12 inhibitors. His lab instituted personalized antiplatelet therapy based on phenotypic and genetic analyses. He holds patents in the fields of interventional cardiology and antithrombotic therapy.
Dr. Gurbel serves on editorial boards for multiple medical journals; his concepts and research have been published in over 1000 abstracts, manuscripts, monographs, books and book chapters. he is now the Director of the Inova Center for Thrombosis Research and Drug Development and the Director, Interventional Cardiology and Cardiovascular Medicine Research at the Inova Heart and Vascular Institute in Falls Church, Virginia.
Consulting and or Honoraria: Astra Zeneca, Boehringer Ingelheim GmbH, Daiichi Sankyo, Merck and Company Inc., CSL, Janssen, New Haven Pharmaceuticals.
Grant Support: Astra Zeneca, Daiichi Sankyo, CSL, Haemoscope Corporation, National
Institute of Health, CORAMED, New Haven Pharmaceuticals.